|
|
|
| |
| Company Profile |
| |
|
Curis, Inc., a therapeutic drug development company, focuses on the discovery and development of products that modulate key regulatory signaling pathways controlling the repair and regeneration of human tissues and organs. The companys product development approach involves using small molecules, proteins or antibodies to modulate these regulatory signaling pathways. The company has developed a significant intellectual property portfolio in major signaling pathways, including the Hedgehog pathway and the Bone Morphogenetic Protein pathway. Curis uses this product development approach to produce various preclinical product candidates in the fields of kidney disease, cancer, neurological disorders, cardiovascular disease, and hair growth regulation. The company conducts research programs both internally, and through strategic alliances and partnerships. It has collaborations and strategic relationships with Genentech, Inc., and Ortho Biotech Products, LP, and Wyeth. Curis licensed its small molecule and antibody antagonists of the Hedgehog signaling pathway to Genentech for applications in cancer therapy. The company was founded in 2000 and is headquartered in Cambridge, Massachusetts.
|
CURIS INC Related |
|
Curis Developing regenerative medicine products.
|
|
CRIS: Profile for Curis, Inc. - Yahoo! Finance See the company profile for Curis, Inc. (CRIS) including business summary, industry/sector information, number of employees, business summary, corporate governance, ...
|
|
CRIS: Summary for Curis, Inc. - Yahoo! Finance Get detailed information on Curis, Inc. ... CURIS INC Financials EDGAR Online Financials(Fri, Oct 31) ... CURIS INC Files SEC form 8-K, Results of Operations ...
|
|
